
<DOC>
<DOCNO>
WSJ900621-0105
</DOCNO>
<DOCID>
900621-0105.
</DOCID>
<HL>
   Financing Business:
   Repligen Corp.
</HL>
<DATE>
06/21/90
</DATE>
<SO>
WALL STREET JOURNAL (J), NO PAGE CITATION
</SO>
<CO>
   RGEN CNTO
</CO>
<IN>
STOCK MARKET, OFFERINGS (STK)
TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)
</IN>
<LP>
   REPLIGEN Corp. sold two million shares of common stock at
$15.50 a share. Of the total, 775,000 shares were offered by
the Cambridge, Mass., biotechnology concern, and 1,225,000
shares were sold by a subsidiary of Centocor Inc. First
Boston Corp, Lehman Brothers and Hambrecht &amp; Quist managed
the offering. Proceeds to the company will be used for
research and development and for other general purposes. The
company won't receive proceeds from the sale by the Centocor
unit. Prior to the offering Repligen had about 8.3 million
shares outstanding.
</LP>
<TEXT>
</TEXT>
</DOC>